Latin America is among the top emerging regions in the world for clinical research, and provides expanding opportunities for biopharmaceutical product development. The region offers rapid access to patients, lower costs of conducting clinical studies, and availability of highly trained professionals for clinical development. Latin America also offers attractive end markets for biopharmaceutical products.
Currently, more than 80% of the regional market share of pharmaceutical sales and growth is distributed among Argentina, Brazil, and Mexico. However, leading biopharmaceutical companies are starting to uncover new opportunities in other Latin American countries, including Costa Rica, the Dominican Republic, Ecuador, Guatemala, Panama, and Venezuela, that have not been traditionally tapped for clinical development. The speakers will review how to unlock this potential through proper planning and a risk-managed approach.
Drawing on extensive expertise, first-hand knowledge, and experience, these experts discuss how biopharmaceutical companies can achieve clinical trial success for both in-country and international marketing approvals. The speakers discuss the pros and cons of conducting clinical research in "non-traditional" Latin American countries, and provide key risk-based approaches.
Untapped Clinical Development Opportunity in Latin America was presented by Dr. Alberto Grignolo, Diego Glancszpigel & Graciela Racaro, Vice President, General Manager, Vice President, Latin America Operations, Senior Director, Latin America Operations, with PAREXEL. This conference aired on 2008-06-05 and is available for download at www.fxconferences.com
